Navigation Links
KaloBios Appoints Harry Lam, Ph.D. as Head of Manufacturing
Date:1/7/2014

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the appointment of Harry Lam, Ph.D. as Head of Manufacturing. Dr. Lam brings to KaloBios more than 28 years of experience in biopharmaceutical manufacturing, including 17 years at Genentech, where he ultimately served as Global Head of Contract Manufacturing Operations, Commercial Drug Substance, for the Roche Group.

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

"Harry Lam joins KaloBios with a wealth of experience in building and leading technical operations and manufacturing teams on a global basis, including the global oversight of drug substance contract manufacturing for all of the Roche Group's products," said David Pritchard, Kalobios' President and Chief Executive Officer. "His experience in directing science and technology on a global basis for drug substance manufacturing will be especially pertinent to KaloBios as we continue to advance the development of our patient-targeted antibody therapeutics towards commercialization."

Dr. Lam was most recently Vice President and Head of Manufacturing for Shire Regenerative Medicine. From 1996 to March 2013, he was an employee of Genentech where he held a variety of increasingly responsible positions related to manufacturing operations, manufacturing science and technology and fermentation operations. In addition to his roles as Global Head of Contract Manufacturing Operations, Commercial Drug Substance (2012-2013), and Senior Director, Global Biologics Drug Substance Manufacturing Science & Technology (2010-2012), during his time at Genentech, Dr. Lam led and managed the technology and operatio
'/>"/>

SOURCE KaloBios Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. FDA Grants Orphan Drug Designation for KaloBios KB001-A in Treatment of Cystic Fibrosis Patients
2. KaloBios Elects Laurie Smaldone Alsup, M.D. to Board
3. KaloBios to Present at Leerink Swann Rare Disease Roundtable
4. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
5. Herb C. Cross to Join KaloBios as Chief Financial Officer
6. KaloBios KB001 Anti-Pseudomonas Antibody Study Published in Pediatric Pulmonology
7. KaloBios to Present at Stifel Healthcare Conference 2013
8. KaloBios Reports First Quarter 2013 Financial Results
9. KaloBios to Present at Needham Healthcare Conference
10. KaloBios Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
11. KaloBios to Present at Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 According ... Product (Diagnostic Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, ... & Indication (AF, VT, WPW) - Global Forecasts to ... expected to reach around ~$4.73 Billion by 2019 with ... 2014 to 2019. Browse   90 ...
(Date:3/27/2015)... , March 27, 2015  RXi Pharmaceuticals ... MirImmune LLC, today announced that they have ... RXi,s novel and proprietary sd-rxRNA® technology for ... The collaboration has the potential to result ... cancer treatments that could be a significant ...
(Date:3/27/2015)... -- Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator ... imaging centers in China , ... under which Concord Medical Services (International) Pte Ltd, ... to acquire the Fortis Surgical Hospital from Fortis ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... ClinOps, LLC, a customer service focused clinical research ... the company as Senior Vice President of Clinical ... 28 years of clinical research experience in multiple ... central nervous system, oncology, etc. , In her ...
... ORANGE COUNTY, Calif., Oct. 26 Beckman Coulter, Inc. (NYSE: ... products that simplify, automate, and innovate complex biomedical testing, announced ... , Oppenheimer & Co. Healthcare Conference - Wednesday, November ... Conference - Friday, November 13, 2009 at 11:00 a.m. ET ...
Cached Medicine Technology:ClinOps, LLC Enhances Senior Management Team With Addition of Connie Andrews as Senior Vice President of Clinical Operations 2
(Date:3/28/2015)... York, NY (PRWEB) March 28, 2015 ... that offers urgent care in Manhattan, recently commemorated its ... care facility in Manhattan. In addition to 24-hour urgent ... ER facilities. , At this time, Emergency Medical ... for abdominal pain, asthma, chest pain, eye injuries, ear ...
(Date:3/28/2015)... March 28, 2015 An article in ... which could prove critical to organizations that deal with ... critical aspect of data security, is worsening . ... security report, every major category out of the twelve ... testing. “With all the craziness that has gone on ...
(Date:3/28/2015)... Pitching speed, player’s height, and pitching for multiple ... injuries, according to new research released today at the American ... , “Our findings indicate that a 10 inch increase in ... a history of injury, a 10 mile per hour increase ... a history of injury, and playing for more than one ...
(Date:3/28/2015)... How best to treat and recover ... orthopaedic medicine. While diagnostic hip injections are commonly performed ... etiology, research presented today at the American Orthopaedic Society ... that pain relief from this diagnostic injection may not ... “Our study looked to assess if the amount of ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Early surgery ... with Type V AC joint injuries, according to new ... today at the American Orthopaedic Society for Sports Medicine’s ... to duty faster when surgery was not performed. , ... 7 receiving surgical treatment and 17 receiving non-surgical therapy. ...
Breaking Medicine News(10 mins):Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2
... have the largest volume of surgical procedures does not necessarily ... the results of a new study in the February issue ... . The findings of studies that suggest the higher ... hospital, the better that hospital,s outcomes will be, has resulted ...
... diseases like Alzheimer,s and Parkinson,s are partly attributable to ... Institutet in Sweden now demonstrate in a paper published ... enzymes can prevent the inflammation and thus constitute a ... microglial cells the nerve system,s primary immune cells ...
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, March ... diabetes were able to get injections of a new insulin drug ... findings still need to be confirmed in another phase of research, ... it were approved for this use. But those caveats aside, ...
... colleagues at Case Western Reserve University School of Medicine have ... a universally fatal, degenerative brain disease for which there is ... and typically leads to death within a year of disease ... of PLoS ONE, a scientific journal produced by ...
... HealthDay Reporter , WEDNESDAY, March 9 (HealthDay News) ... kids, brains are developing an ability to help fight ... Over a three-year period, researchers from Oregon and California studied ... insight into the brain,s wiring during adolescence, finding the most ...
... WEDNESDAY, March 9 (HealthDay News) -- Stroke survivors recover ... involved in their exercise therapy, a new European study ... stroke survivors found that adding family-assisted exercise therapy to ... distance walked, and ability to perform activities of daily ...
Cached Medicine News:Health News:Referral to high-volume hospitals for operations fails to improve outcomes statewide 2Health News:New Drug May Trim Insulin Injections to Just 3 a Week 2Health News:Researchers identify new biomarker for Creutzfeldt-Jakob disease, the human form of mad cow disease 2Health News:Researchers identify new biomarker for Creutzfeldt-Jakob disease, the human form of mad cow disease 3Health News:As Peer Pressure Increases, So Does Brain's Ability to Resist It 2Health News:As Peer Pressure Increases, So Does Brain's Ability to Resist It 3Health News:Family Involvement Helps Stroke Patients With Rehab 2
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
The Acceava pregnancy urine dipstick test provides qualitative determination of human chorionic gonadatropin in urine for early detection of pregnancy....
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
The Acceava Trichomonas Rapid Test is an immunochromatographic assay that detects pathogen antigens directly from vaginal swabs. Results are rapid, occurring within approximately 10 minutes....
Medicine Products: